International companies leverage AI to boost disease awareness

Tencent, a Chinese multinational investment holding conglomerate,  and Merck KGaA, a German-based pharmaceutical, life sciences and technology company, are collaborating to increase disease awareness and provide more accessible healthcare services via digital platforms in China by leveraging AI and big data.

“We want to build on advanced internet platforms and artificial intelligence, big data and cloud computing capabilities, and work with partners to make healthcare in China more convenient and efficient for all patients,” Zhang Meng, vice president of Tencent Medical, said in a prepared statement.

Last year, Tencent partnered with healthcare firm Medopad to train systems to use AI to better diagnose Parkinson’s disease.

Under the agreement, the companies plan to create intelligent digital healthcare services to increase public knowledge of diseases, patients’ understanding of disease symptoms and effective treatment options, as well as provide more convenient and smarter medical services. The areas of focus will include: allergies, infertility, diabetes, thyroid disorders, cardiovascular diseases and metastatic colorectal cancer.

The companies also plan to explore the use of “AI doctors” to provide more comprehensive disease awareness education and treatment services for various diseases.

“In this collaboration with Tencent, we will jointly explore the innovative combination of patient-centric healthcare management and digital platforms, which brings us one step closer to reaching our mission of transforming the lives of 40 million patients in China by 2025,” Rogier Janssens, managing director and general manager of Merck KGaA’s Biopharma Business, said in a statement. 

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”